Remarkable Alteration of PD-L1 Expression after Immune Checkpoint Therapy in Patients with Non-Small-Cell Lung Cancer: Two Autopsy Case Reports

Remarkable Alteration of PD-L1 Expression after Immune Checkpoint Therapy in Patients with Non-Small-Cell Lung Cancer: Two Autopsy Case Reports

Pembrolizumab is an immune checkpoint inhibitor (ICI), currently recommended as the first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) showing ≥50% expression of programmed death-ligand 1 (PD-L1). Previously it was reported that platinum-based chemotherapy m...

Full description

Bibliographic Details
Main Authors: Toshiaki Takahashi, Akiko Tateishi, Andrey Bychkov, Junya Fukuoka
Format: Article
Language:English
Published: MDPI AG 2019-05-01
Series:International Journal of Molecular Sciences
Subjects:
NSCLC
immune therapy
Pembrolizumab
immune checkpoint inhibitors
PD-L1
tumor microenvironment
Online Access:https://www.mdpi.com/1422-0067/20/10/2578

Internet

https://www.mdpi.com/1422-0067/20/10/2578

Similar Items